The team headed by ICREA researcher, Lluís Ribas, has published a study in Cell Report describing a functional network that coordinates protein synthesis and DNA replication in animal mitochondria.
These findings contribute to our understanding of the mechanisms involved in mitochondrial dysregulation associated with diseases such as MELAS and MERRF and may help to identify new therapeutic approaches.
Innovaspain.com has dedicated an article to the research undertaken by Iproteos, a company specialized in the discovery of drugs for diseases of the nervous system. This spin-off company of IRB Barcelona has demonstrated the effectiveness of a novel compound, IPR-19, to reverse the cognitive deficit associated with schizophrenia in mouse models. At present, this peptide is in the preclinical phase.
Agencia SINC echoes the interest of pharmaceutical multinationals in Iproteos. Founded in 2011 by Teresa Tarragó, this biotechnology company is a spin-off of IRB Barcelona. Since then, Tarragó aimed to convert a molecule (IPR-19) discovered during her research into a drug. This molecule has great potential for the treatment of cognitive problems caused by schizophrenia.